サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427828

オンコロジー向けジェネリック無菌注射剤の世界市場レポート 2024

Generic Oncology Sterile Injectable Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
オンコロジー向けジェネリック無菌注射剤の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

オンコロジー向けジェネリック無菌注射剤の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.3%の年間平均成長率（CAGR）で270億4,000万米ドルに成長すると予想されます。予測期間で予想される成長は、ヘルスケアへの投資の拡大、腫瘍学におけるバイオシミラーの採用、がん治療薬のパイプラインの拡大、世界のがん発生率の増加、ジェネリック滅菌注射剤の規制経路の確立によるものと考えられます。予測期間中に予想される主な動向には、複雑なジェネリック腫瘍薬の開発、先進的な製造技術の利用の高まり、腫瘍学における個別化医療の急増、バイオシミラー競合の重視の高まり、サプライチェーン管理におけるデジタル技術の統合などが含まれます。

オンコロジー向けジェネリック無菌注射剤市場の予想される成長は、がんの罹患率の増加によって促進されると予想されます。異常細胞の制御されない増殖を特徴とするがんは、体内のさまざまな器官や組織に影響を与える可能性があります。がんの罹患率の増加に寄与する要因には、喫煙、放射線への曝露、発がん性物質、肥満、遺伝子変異などが含まれます。 オンコロジー向けジェネリック無菌注射剤製品は、がん細胞の増殖を阻害し、腫瘍サイズを縮小する上で重要な役割を果たします。米国に本拠を置く非営利医療団体であるAmerican Cancer Society Inc.は、2023年には190万人を超える新たながん症例が診断されると予測しており、2021年に新たに診断された180万人以上と比べて増加しています。したがって、がんの有病率の増加は、オンコロジー向けジェネリック無菌注射剤市場の拡大の背後にある重要な推進力となっています。

オンコロジー向けジェネリック無菌注射剤市場の成長は、腫瘍学サービスへの政府投資の増加によって促進されると予想されます。政府投資には、特定の経済的、社会的、または戦略的目標を達成することを目的とした、さまざまなプロジェクト、プログラム、取り組みへの公的資金の配分が含まれます。がん調査、治療施設、ヘルスケアインフラに対する政府の資金提供の強化は、腫瘍学サービスの利用しやすさと質の向上に貢献しています。たとえば、2021年10月、スティーブン・ドネリー保健大臣は、アイルランドの2022年度予算でがんサービスのための新たな開発資金として2,000万ユーロ（21.89ドル）を追加すると発表しました。したがって、腫瘍学サービスへの政府投資の増加は、オンコロジー向けジェネリック無菌注射剤市場の成長を推進する上で極めて重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のオンコロジー向けジェネリック無菌注射剤市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 化学療法
  • 代謝拮抗物質
  • 植物アルカロイド
  • 抗腫瘍性抗生物質
  • その他の製品
  • 世界のオンコロジー向けジェネリック無菌注射剤市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のオンコロジー向けジェネリック無菌注射剤市場、疾患適応別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 卵巣がん
  • 乳がん
  • 肺がん
  • 膵臓がん
  • その他の適応症

第7章 地域および国の分析

  • 世界のオンコロジー向けジェネリック無菌注射剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のオンコロジー向けジェネリック無菌注射剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • オンコロジー向けジェネリック無菌注射剤市場の競合情勢
  • オンコロジー向けジェネリック無菌注射剤市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • Merck &Co Inc.
    • Sanofi SA
    • AstraZeneca plc

第31章 その他の大手および革新的な企業

  • GlaxoSmithKline Plc
  • Eli Lilly and Company
  • Amgen Inc.
  • Novo Nordisk A/S
  • Baxter International Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Hikma Pharmaceuticals plc
  • Amneal Pharmaceuticals LLC

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13672

A generic oncology sterile injectable is a biologic drug containing the same active ingredients as the branded version but differing only in the inactive components. It is utilized in the treatment of various cancer types, including breast, prostate, and colorectal cancers.

The primary products within the category of generic oncology sterile injectables include chemotherapy, antimetabolites, plant alkaloids, antitumor antibiotics, and other related medications. Chemotherapy, a type of treatment that employs potent chemicals to eliminate rapidly dividing cells in the body, is among the key components. These drugs are made available through diverse distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are employed in the treatment of ovarian cancer, breast cancer, lung cancer, pancreatic cancer, and various other malignancies.

The generic oncology sterile injectable research report is one of a series of new reports from The Business Research Company that provides generic oncology sterile injectable market statistics, including the generic oncology sterile injectable industry's global market size, regional shares, competitors with generic oncology sterile injectable market share, detailed generic oncology sterile injectable market segments, market trends and opportunities, and any further data you may need to thrive in the generic oncology sterile injectable industry. This generic oncology sterile injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The generic oncology sterile injectable market size has grown rapidly in recent years. It will grow from $15.68 billion in 2023 to $17.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth observed in the historical period can be attributed to the expiration of patents for branded oncology drugs, a rise in the prevalence of cancer, an increased emphasis on cost-effective healthcare solutions, regulatory backing for generic medications, and the expansion of generic pharmaceutical companies.

The generic oncology sterile injectable market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth in the forecast period can be ascribed to the escalation in healthcare investments, the adoption of biosimilars in oncology, the expansion of pipelines for oncology drugs, an increase in global cancer incidence, and the establishment of regulatory pathways for generic sterile injectables. Major trends expected in the forecast period encompass the development of complex generic oncology drugs, the heightened use of advanced manufacturing technologies, the surge of personalized medicine in oncology, a growing emphasis on biosimilar competition, and the integration of digital technologies in supply chain management.

The anticipated growth in the generic oncology sterile injectable market is expected to be driven by the rising prevalence of cancer. Cancer, characterized by the uncontrolled proliferation of abnormal cells, can affect various organs or tissues in the body. Factors contributing to the increasing prevalence of cancer include smoking, exposure to radiation, carcinogenic substances, obesity, and genetic mutations. Generic oncology sterile injectable products play a crucial role in inhibiting the growth of cancer cells and reducing tumor size. In 2023, the American Cancer Society Inc., a non-profit health group based in the United States, projects that over 1.9 million new cancer cases will be diagnosed, marking an increase compared to the more than 1.8 million new cases diagnosed in 2021. Consequently, the growing prevalence of cancer is a key driver behind the expansion of the oncology sterile injectable market.

The growth of the generic oncology sterile injectable market is expected to be fueled by increasing government investments in oncology services. Government investments involve the allocation of public funds to various projects, programs, and initiatives with the goal of achieving specific economic, social, or strategic objectives. Enhanced government funding in cancer research, treatment facilities, and healthcare infrastructure contributes to improved accessibility and quality of oncology services. For example, in October 2021, the Minister for Health, Stephen Donnelly, announced an additional €20 million ($21.89) in new development funding for cancer services in Budget 2022 in Ireland. Therefore, the heightened government investments in oncology services play a pivotal role in propelling the growth of the oncology sterile injectable market.

Product innovation is a prominent trend gaining traction in the generic oncology sterile injectable market. Leading companies in the sector are actively involved in developing innovative products to maintain their competitive edge. For example, in July 2022, Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced Bortezomib for injection, a generic version of Velcade. This injection, available in a single-dose vial with a dosage of 3.5 mg per 10 mL, is designed for intravenous or subcutaneous administration and is utilized in cancer treatment.

Major players in the generic oncology sterile injectable market are strategically forming alliances to fortify their market positions. Strategic collaborations enable companies to join forces with other entities possessing the required expertise, transforming conceptual ideas into tangible realities. For instance, in July 2021, Terumo, a Japanese medical technology company, and the University Medical Centre Utrecht (UMCU) inked a memorandum of understanding (MoU) to extend their partnership in the realm of oncology. Through this MoU, Terumo and UMCU aim to transfer technology and develop solutions for generic oncology, encompassing tumor ablation and chemoembolization.

In April 2022, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, completed the acquisition of Custopharm Inc. for $425 million. This strategic move is anticipated to enhance Hikma Pharmaceuticals' injectables business by incorporating a compelling portfolio of marketed products. Custopharm Inc. is a US-based company specializing in generic sterile injectables.

Major companies operating in the generic oncology sterile injectable market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Sun Pharmaceutical Industries Inc., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Zydus Lifesciences Limited, Nichi-Iko Pharmaceutical Co. Ltd., Biocon Ltd., Jubilant Pharmova Ltd., Gland Pharma Limited, Apotex Inc., Accord Healthcare Ltd.

North America was the largest region in the generic oncology sterile injectable market in 2023. Asia-Pacific is expected to be the generic oncology sterile injectable market report during the fastest-growing region in the forecast period. The regions covered in the generic oncology sterile injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generic oncology sterile injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generic oncology sterile injectable market consists of sales of paclitaxel injection, doxorubicin hydrochloride injection, and gemcitabine hydrochloride injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Oncology Sterile Injectable Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic oncology sterile injectable market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic oncology sterile injectable ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic oncology sterile injectable market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Chemotherapy; Antimetabolites; Plant Alkaloids; Antitumor Antibiotics; Other Products
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 3) By Disease Indication: Ovarian Cancer; Breast Cancer; Lung Cancer; Pancreatic Cancer; Other Indications
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; Sanofi S.A.; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Oncology Sterile Injectable Market Characteristics

3. Generic Oncology Sterile Injectable Market Trends And Strategies

4. Generic Oncology Sterile Injectable Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Generic Oncology Sterile Injectable Market Size and Growth

  • 5.1. Global Generic Oncology Sterile Injectable Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Generic Oncology Sterile Injectable Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Generic Oncology Sterile Injectable Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Generic Oncology Sterile Injectable Market Segmentation

  • 6.1. Global Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Antimetabolites
  • Plant Alkaloids
  • Antitumor Antibiotics
  • Other Products
  • 6.2. Global Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.3. Global Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ovarian Cancer
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Other Indications

7. Generic Oncology Sterile Injectable Market Regional And Country Analysis

  • 7.1. Global Generic Oncology Sterile Injectable Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Generic Oncology Sterile Injectable Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Generic Oncology Sterile Injectable Market

  • 8.1. Asia-Pacific Generic Oncology Sterile Injectable Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Generic Oncology Sterile Injectable Market

  • 9.1. China Generic Oncology Sterile Injectable Market Overview
  • 9.2. China Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Generic Oncology Sterile Injectable Market

  • 10.1. India Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Generic Oncology Sterile Injectable Market

  • 11.1. Japan Generic Oncology Sterile Injectable Market Overview
  • 11.2. Japan Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Generic Oncology Sterile Injectable Market

  • 12.1. Australia Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Generic Oncology Sterile Injectable Market

  • 13.1. Indonesia Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Generic Oncology Sterile Injectable Market

  • 14.1. South Korea Generic Oncology Sterile Injectable Market Overview
  • 14.2. South Korea Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Generic Oncology Sterile Injectable Market

  • 15.1. Western Europe Generic Oncology Sterile Injectable Market Overview
  • 15.2. Western Europe Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Generic Oncology Sterile Injectable Market

  • 16.1. UK Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Generic Oncology Sterile Injectable Market

  • 17.1. Germany Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Generic Oncology Sterile Injectable Market

  • 18.1. France Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Generic Oncology Sterile Injectable Market

  • 19.1. Italy Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Generic Oncology Sterile Injectable Market

  • 20.1. Spain Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Generic Oncology Sterile Injectable Market

  • 21.1. Eastern Europe Generic Oncology Sterile Injectable Market Overview
  • 21.2. Eastern Europe Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Generic Oncology Sterile Injectable Market

  • 22.1. Russia Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Generic Oncology Sterile Injectable Market

  • 23.1. North America Generic Oncology Sterile Injectable Market Overview
  • 23.2. North America Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Generic Oncology Sterile Injectable Market

  • 24.1. USA Generic Oncology Sterile Injectable Market Overview
  • 24.2. USA Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Generic Oncology Sterile Injectable Market

  • 25.1. Canada Generic Oncology Sterile Injectable Market Overview
  • 25.2. Canada Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Generic Oncology Sterile Injectable Market

  • 26.1. South America Generic Oncology Sterile Injectable Market Overview
  • 26.2. South America Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Generic Oncology Sterile Injectable Market

  • 27.1. Brazil Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Generic Oncology Sterile Injectable Market

  • 28.1. Middle East Generic Oncology Sterile Injectable Market Overview
  • 28.2. Middle East Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Generic Oncology Sterile Injectable Market

  • 29.1. Africa Generic Oncology Sterile Injectable Market Overview
  • 29.2. Africa Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Generic Oncology Sterile Injectable Market Competitive Landscape And Company Profiles

  • 30.1. Generic Oncology Sterile Injectable Market Competitive Landscape
  • 30.2. Generic Oncology Sterile Injectable Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Generic Oncology Sterile Injectable Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline Plc
  • 31.2. Eli Lilly and Company
  • 31.3. Amgen Inc.
  • 31.4. Novo Nordisk A/S
  • 31.5. Baxter International Inc.
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. Mylan N.V.
  • 31.8. Sandoz International GmbH
  • 31.9. Fresenius Kabi AG
  • 31.10. Sun Pharmaceutical Industries Inc.
  • 31.11. Dr. Reddy's Laboratories Ltd.
  • 31.12. Aurobindo Pharma Limited
  • 31.13. Cipla Inc.
  • 31.14. Hikma Pharmaceuticals plc
  • 31.15. Amneal Pharmaceuticals LLC

32. Global Generic Oncology Sterile Injectable Market Competitive Benchmarking

33. Global Generic Oncology Sterile Injectable Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Generic Oncology Sterile Injectable Market

35. Generic Oncology Sterile Injectable Market Future Outlook and Potential Analysis

  • 35.1 Generic Oncology Sterile Injectable Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Generic Oncology Sterile Injectable Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Generic Oncology Sterile Injectable Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer